Evaluating the predictive power of a set of adrenergic and mesenchymal coding - and - noncoding RNAs in neuroblastoma.

01 March 2024 → 28 February 2026
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Cancer diagnosis
    • Oncology not elsewhere classified
    • Pediatrics
    • Cancer diagnosis
    • Oncology not elsewhere classified
    • Pediatrics
mRN neuroblastoma mRNA pediatric non-coding RNA adrenergic
Project description

The SIOPEN Circulating RNA Committee (CRC) has designed and validated an RTqPCR test, detecting adrenergic mRNAs in blood and bone marrow aspirates, allowing identification of children with high-risk neuroblastoma disease. Recently, it became clear that neuroblastoma contains cells with an adrenergic or mesenchymal signature, and that the number of mesenchymal cells increases in post-treatment and relapse tumours. In addition, it has become clear that non-coding RNA transcripts have an important role in neuroblastomas development, and might be used to detect residual neuroblastomas cells. Therefore, in this project we will investigate the hypothesis that a combination of mesenchymal and adrenergic neuroblastoma RNAs – coding and non-coding - will most reliably detect clinically relevant disease.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the authority can be held responsible for them.